BIOMARIN PHARMACEUTICAL INC (BMRN)

Quarterly Report Filed: 2026-05-05

Key Insights

The filing content provided is severely truncated and consists primarily of XBRL metadata tags without substantive financial data, making it impossible to assess actual revenue trends, profitability, or financial performance for Q1 2026.
The presence of extensive derivative hedging instruments (foreign exchange contracts) and multiple investment categories suggests the company maintains active treasury management and currency risk mitigation strategies.
The filing structure indicates BioMarin tracks product revenue separately from royalty and other revenue streams, suggesting a diversified revenue model beyond primary product sales.

Current Report Filed: 2026-04-27

Key Insights

BioMarin completed its acquisition of Amicus Therapeutics for $14.50 per share in cash on April 27, 2026, representing a significant strategic combination in the rare disease pharmaceutical space that expands BioMarin's product portfolio and market presence.
The company financed the Amicus acquisition through $2.8 billion in senior secured term loans ($2.0B Term Loan B and $800M Term Loan A) plus $600M revolving credit facility, with Term B loans maturing in 7 years at 1.75% margin and Term A loans maturing in 5 years at variable margins of 1.00-1.75%.
BioMarin incurred substantial debt to fund the merger, with the company relying on previously issued $500M of 5.500% Senior Notes due 2034 and existing cash, creating meaningful leverage that investors should monitor for deleveraging progress and cash flow impact in future quarters.
All Amicus equity awards were converted to cash payments at the $14.50 merger price, including in-the-money options, RSUs, and performance-vesting RSUs, indicating a complete equity elimination and potential for significant employee transition considerations post-close.

Current Report Filed: 2026-04-23

Key Insights

French FDI regulatory clearance obtained on April 23, 2026, satisfying the final significant condition to closing the Amicus Therapeutics merger, with expected closing scheduled for April 27, 2026.
The merger agreement with Amicus was signed December 19, 2025, and regulatory approval process has progressed through multiple jurisdictions, indicating sustained momentum toward deal completion.
Remaining conditions to closing are only those customary matters satisfied at closing, substantially de-risking the transaction and reducing uncertainty around deal completion timing.

Insider Trading Filed: 2026-03-19

Key Insights

George Eric Davis, the EVP and Chief Legal Officer of BioMarin Pharmaceutical Inc., disposed of 1,273 shares of the company's common stock on March 18, 2026 at a price of $56.05 per share.
This transaction reduced Davis's direct beneficial ownership of BioMarin's common stock to 78,560 shares.
Insider selling can sometimes signal a lack of confidence in the company's future performance, but a single transaction may not be indicative of a broader trend.

Insider Trading Filed: 2026-03-19

Key Insights

Charles Greg Guyer, the EVP and Chief Technical Officer of BioMarin Pharmaceutical Inc., sold 1,693 shares of the company's common stock on March 17, 2026 at $56.05 per share.
Following the reported transaction, Guyer still holds 84,140 shares of BioMarin common stock directly.
This insider sell transaction, while not a large amount, could be seen as a somewhat negative signal about the executive's confidence in the company's short-term prospects.

Insider Trading Filed: 2026-03-19

Key Insights

Brian Mueller, the EVP and Chief Financial Officer of BioMarin Pharmaceutical Inc. (BMRN), disposed of 2,117 shares of the company's common stock on March 17, 2026 at a price of $56.05 per share.
Following this transaction, Mueller's direct beneficial ownership in BMRN decreased to 123,314 shares.
This insider sale, while not a large transaction, may indicate that the executive has a moderately positive sentiment about the company's current valuation and future prospects.

Insider Trading Filed: 2026-03-19

Key Insights

The reporting person, Alexander Hardy, is the Chief Executive Officer of BioMarin Pharmaceutical Inc. and a director, indicating his influential role in the company's leadership and operations.
Alexander Hardy disposed of 4,252 shares of BioMarin's common stock on March 17, 2026, reducing his direct beneficial ownership to 214,635 shares.
The transaction was executed at a price of $56.05 per share, which may provide insights into the market's perception of BioMarin's stock value at the time.

Insider Trading Filed: 2026-03-18

Key Insights

The reporting person Gregory R. Friberg, EVP and Chief R&D Officer, acquired 19,150 shares of common stock through restricted stock units on March 16, 2026.
Friberg also disposed of 1,629 shares of common stock through a sell-to-cover transaction on March 17, 2026 at a price of $56.05 per share.
Friberg now holds 55,099 shares of common stock directly, representing his total beneficial ownership in the company.

Insider Trading Filed: 2026-03-18

Key Insights

Cristin Hubbard, the EVP and Chief Commercial Officer of BioMarin Pharmaceutical Inc. (BMRN), acquired 15,410 shares of common stock through a restricted stock unit grant on March 16, 2026.
Hubbard also disposed of 1,245 shares of common stock through a tax withholding transaction on March 17, 2026, at a price of $56.05 per share.
Hubbard's total direct ownership in the company increased to 44,790 shares following the reported transactions.

Insider Trading Filed: 2026-03-17

Key Insights

The CEO Alexander Hardy has acquired a significant number of 62,440 shares of BioMarin Pharmaceutical, indicating his confidence in the company's future performance.
The CEO has also exercised stock options for 89,200 shares, further increasing his stake in the company.
The insider buying activity, combined with the CEO's existing holdings of 156,447 shares, suggests strong leadership alignment with shareholders' interests.

Insider Trading Filed: 2026-03-17

Key Insights

The reporting person, Charles Greg Guyer, the EVP and Chief Technical Officer of BioMarin Pharmaceutical Inc., acquired 14,990 additional shares of the company's common stock on March 16, 2026 through a restricted stock unit grant.
Guyer also disposed of 9,109 shares of the company's common stock on March 13, 2026, likely to cover tax withholding obligations related to the vesting of equity awards.
Guyer's total direct holdings in BioMarin Pharmaceutical increased from 70,843 shares to 85,833 shares following the reported transactions, indicating his continued commitment to the company.

Insider Trading Filed: 2026-03-17

Key Insights

George Eric Davis, the EVP and Chief Legal Officer of BioMarin Pharmaceutical, acquired 14,570 shares of the company's common stock through restricted stock units on March 16, 2026, increasing his direct beneficial ownership to 79,833 shares.
Davis also disposed of 7,177 shares of the company's common stock on the same date, likely for tax withholding purposes associated with the restricted stock unit vesting.
The reporting person's direct holdings have been adjusted by 13 shares to correct a previous clerical error, indicating the company's attention to detail in its reporting.

Insider Trading Filed: 2026-03-17

Key Insights

Brian Mueller, the EVP and Chief Financial Officer of BioMarin Pharmaceutical Inc., acquired 18,740 additional shares of the company's common stock through a restricted stock unit grant on March 16, 2026.
Mueller disposed of 9,945 shares of BioMarin common stock on March 13, 2026, likely to cover tax withholding obligations related to the vesting of equity awards.
The reported transactions indicate that the CFO is maintaining a significant direct ownership position in the company, aligning his interests with those of shareholders.

Current Report Filed: 2026-03-16

Key Insights

BioMarin has decided to discontinue dosing and enrollment in its Phase 2 trials for VOXZOGO in Turner Syndrome, SHOX-deficiency, and Aggrecan (ACAN)-deficiency due to the occurrence of several slipped capital femoral epiphysis (SCFE) events in ongoing investigator-sponsored trials.
The Phase 2 CANOPY trials of VOXZOGO in children with Noonan syndrome, as well as those living with idiopathic short stature (ISS) without ACAN-deficiency, will continue as planned.
BioMarin has a strong safety profile for VOXZOGO, with no observed SCFE events in over 5,000 infants and children who have received the treatment for achondroplasia, or in its clinical trials for hypochondroplasia.

Annual Report Filed: 2026-02-26

Key Insights

BioMarin Pharmaceutical Inc. reported stable revenue and earnings performance for the 2025 fiscal year, with continued growth in its core product portfolio.
The company maintained its research and development spending, investing in its pipeline of experimental therapies targeting rare genetic disorders.
BioMarin's balance sheet remains healthy, with a strong cash position and manageable debt levels, providing financial flexibility for future investments.

Current Report Filed: 2026-02-23

Key Insights

BioMarin Pharmaceutical Inc. (BMRN) reported its Q4 2025 financial results, providing an update on its operations and financial performance.
The company did not disclose any material agreements, leadership changes, or earnings surprises in this 8-K filing.
Without additional details on the company's financial results or other key business developments, the significance of this filing appears to be routine.

Current Report Filed: 2026-02-12

Key Insights

BioMarin Pharmaceutical Inc. completed a $850 million private placement of senior notes due in 2026 with an interest rate of 5.500% to fund the pending acquisition of Amicus Therapeutics, Inc.
The company also secured a new $2 billion senior secured term loan facility and a $800 million senior secured term loan facility, as well as a $600 million senior secured revolving credit facility, to finance the acquisition.
The indenture for the notes includes covenants that restrict BioMarin's ability to take certain actions, such as incurring additional debt, paying dividends, or making investments, unless certain conditions are met.

Current Report Filed: 2026-01-29

Key Insights

BioMarin is raising $850 million through a private placement of 5.500% senior unsecured notes due 2034 to help fund the acquisition of Amicus Therapeutics.
In addition to the notes offering, BioMarin has also secured a new $2 billion senior secured term loan facility and a $600 million senior secured revolving credit facility to finance the Amicus acquisition.
The notes will be guaranteed by certain of BioMarin's subsidiaries, including Amicus and its subsidiaries after the acquisition closes, and will rank equally with BioMarin's other unsubordinated debt.

Current Report Filed: 2026-01-26

Key Insights

BioMarin Pharmaceutical reported preliminary unaudited results for 2025, including total revenues of approximately $3.2 billion and VOXZOGO revenues of $920 million, indicating strong performance.
The company plans to raise $850 million through a private placement of senior unsecured notes due 2034 to fund its acquisition of Amicus Therapeutics, along with a new $2.8 billion senior secured credit facility.
The preliminary pro forma financial information provides insights into the expected impact of the Amicus Therapeutics acquisition on BioMarin's financial position and performance.

Insider Trading Filed: 2026-01-22

Key Insights

The reporting person, Rashmi Virendra Ramchandani, acquired 18,540 shares of BioMarin Pharmaceutical Inc. common stock and an additional 7,070 shares, indicating a significant increase in their equity ownership position.
Ramchandani also received 18,220 stock options with an exercise price of $56.31, vesting over a 9-year period, further aligning their incentives with long-term shareholder value creation.
The transaction suggests the reporting person has a positive outlook on the company's future prospects and is willing to increase their financial stake in BioMarin Pharmaceutical.

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Important Information